Grufity logoGrufity logo

NUVA

39.83USD+1.06(+2.73%)Delayedas of 07 Dec 2022, 10:56 am

NuVasive Inc

Market Summary

USD39.83+1.06Delayedas of 07 Dec 2022, 10:56 am
2.73%

NUVA Alerts

NUVA Stock Price

RSI Chart

Valuation

Market Cap

2.3B

Price/Earnings

-57.55

Price/Sales

1.96

Price/Cashflow

13.49

MarketCap/EBT

-66.36

Price/Sales

Profitability

Operating Margin

73.51%

EBT Margin

-2.96%

Return on Equity

-4.85%

Return on Assets

-1.84%

Fundamentals

Revenue

Revenue (TTM)

1.2B

Revenue Y/Y

9.03%

Revenue Q/Q

-4.89%

Earnings

Earnings (TTM)

-20.4M

Earnings Y/Y

90.86%

Earnings Q/Q

-121.39%

Price Action

52 Week Range

35.1760.47
(Low)(High)

Last 7 days

4.3%

Last 30 days

-6.1%

Last 90 days

-14.5%

Trailing 12 Months

-24.8%

Financial Health

Current Ratio

1.17

Investor Care

Shares Dilution (1Y)

0.77%

Diluted EPS (TTM)

-0.42

Peers (Alternatives to NuVasive)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-15.19% 31.17%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
11.64% -6.61%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
11.18% -17.75%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
10.66% 2.81%
38.21
3.25
-6.81% -14.96%
61.8B
12.6B
8.58% 10.96%
69.9
5.01
9.56% 51.89%
43.9B
5.4B
5.44% -35.45%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
9.55% 2.62%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
33.31% -13.25%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-6.98% -2.00%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
14.84% -68.69%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
23.76% 23.16%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
2.27% -17.18%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
15.03% -14.89%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-5.60% -30.91%
-16.43
2.57
-8.79% -175.19%

Financials for NuVasive

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue2.1%1,1991,1741,1591,1391,129
Gross Profit3.8%869837829817805
Operating Expenses0.5%831827841829769
  S&GA Expenses1.3%636628624610594
  R&D Expenses0.3%9898949389
Earnings Before Taxes61.0%-13.55-34.75-26.41-58.38-23.44
Net Income49.1%-20.40-40.07-37.37-64.09-25.66
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets0.0%2,1752,1742,1612,1542,134
  Current Assets2.4%843823792802770
    Cash Equivalents5.1%238226205246235
  Inventory2.8%341332324316311
  Net PPE0.5%304302---
  Goodwill-0.8%625630637633633
  Current Liabilities-0.6%697701249201195
Shareholder's Equity0.7%832827812795824
  Retained Earnings-3.1%6264654682
  Additional Paid-In Capital0.3%1,4581,4531,4421,4351,425
Accumulated Depreciation-503----
Shares Outstanding0.0%5252525252
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-6.5%160171157182217
  Share Based Compensation-0.6%2627242526
Cashflow From Investing-4.8%-139.84-133.46-167.58-136.06-104.14
Cashflow From Financing2.2%-9.54-9.76-16.23-653.35-653.03
  Buy Backs-3.1%771498

Risks

What is the probability of a big loss on NUVA?

89.6%


Probability that NuVasive stock will be more than 20% underwater in next one year

69.6%


Probability that NuVasive stock will be more than 30% underwater in next one year.

28.1%


Probability that NuVasive stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NUVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if NuVasive was unfortunately bought at previous high price.

Returns

Cumulative Returns on NUVA

10.7%


10-Year Cumulative Returns

-3.7%


7-Year Cumulative Returns

-7.7%


5-Year Cumulative Returns

-19.7%


3-Year Cumulative Returns

What are the long-term rolling returns for NUVA?

FIve years rolling returns for NuVasive.

Which funds bought or sold NUVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
282,000
282,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.54
-400,000
2,868,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-113,000
-
-%
2022-11-16
Retirement Systems of Alabama
REDUCED
-0.58
-384,000
2,986,000
0.01%
2022-11-16
GLENMEDE TRUST CO NA
REDUCED
-10.84
-2,698,000
10,437,000
0.07%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-37.6
-5,878,000
7,363,000
-%
2022-11-15
NOMURA HOLDINGS INC
NEW
-
263,000
263,000
-%
2022-11-15
Verdence Capital Advisors LLC
ADDED
4.59
-15,000
210,000
0.03%
2022-11-15
BNP PARIBAS ARBITRAGE, SA
SOLD OFF
-100
-1,918,810
-
-%

1–10 of 38

Latest Funds Activity

Are funds buying NUVA calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own NUVA

NuVasive News

InvestorsObserver

How Will the Market React to NuVasive, Inc. (NUVA) Stock Getting a Bullish Rating.46 hours ago

NUVA Fair Value

Recent SEC filings of NuVasive

View All Filings
Date Filed Form Type Document
Nov 09, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report
Oct 06, 2022
8-K
Current Report
Sep 08, 2022
3
Insider Trading

Latest Insider Trading transactions for NUVA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-06-01
Norwalk Leslie V
ACQUIRED
-
-
1,547
-
2022-05-28
Kadia Siddhartha
ACQUIRED
-
-
3,739
-
2022-05-11
Rosenberg Donald J
ACQUIRED
-
-
13,326
-
2022-04-13
Barry James Christopher
SOLD
-290,000
58
-5,000
Chief Executive Officer
2022-03-28
Barry James Christopher
SOLD
-275,000
55
-5,000
Chief Executive Officer
2022-03-01
Barry James Christopher
ACQUIRED
-
-
53,523
Chief Executive Officer
2022-03-01
Barry James Christopher
SOLD (Taxes)
-1,133,370
54.51
-20,792
Chief Executive Officer
2022-03-01
SISITSKY NATHANIEL
SOLD (Taxes)
-156,335
54.51
-2,868
SVP & General Counsel
2022-03-01
SISITSKY NATHANIEL
ACQUIRED
-
-
8,029
SVP & General Counsel
2022-03-01
Calafiore Massimo
ACQUIRED
-
-
8,699
EVP, Chief Commercial Officer

1–10 of 50

J. Christopher Barry
2900
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

NUVA Income Statement

2022-09-30
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net sales:    
Net sales$ 295,280$ 270,836$ 896,493$ 836,913
Cost of sales (excluding below amortization of intangible assets):    
Cost of sales80,87288,652245,727238,743
Gross profit214,408182,184650,766598,170
Operating expenses:    
Selling, general and administrative154,005146,056474,982449,407
Research and development23,66623,40572,93767,393
Amortization of intangible assets12,15714,80537,82643,230
Business transition costs2,8114,551(1,753)21,688
Total operating expenses192,639188,817583,992581,718
Interest and other expense, net:    
Interest income820231,125119
Interest expense(4,352)(4,320)(13,083)(16,738)
Other expense, net(21,053)(13,082)(34,490)(24,339)
Total interest and other expense, net(24,585)(17,379)(46,448)(40,958)
(Loss) income before income taxes(2,816)(24,012)20,326(24,506)
Income tax benefit (expense)8392,373(3,995)(2,844)
Consolidated net (loss) income$ (1,977)$ (21,639)$ 16,331$ (27,350)
Net (loss) income per share:    
Basic (in dollars per share)$ (0.04)$ (0.42)$ 0.31$ (0.53)
Diluted (in dollars per share)$ (0.04)$ (0.42)$ 0.31$ (0.53)
Weighted average shares outstanding:    
Basic (in shares)52,06751,66951,97451,539
Diluted (in shares)52,06751,66952,51251,539
Product [Member]    
Net sales:    
Net sales$ 267,208$ 247,061$ 813,600$ 759,275
Cost of sales (excluding below amortization of intangible assets):    
Cost of sales59,22069,609181,670181,495
Service [Member]    
Net sales:    
Net sales28,07223,77582,89377,638
Cost of sales (excluding below amortization of intangible assets):    
Cost of sales$ 21,652$ 19,043$ 64,057$ 57,248

NUVA Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 237,500$ 246,091
Accounts receivable, net of allowances of $18,702 and $21,064, respectively235,582214,398
Inventory, net340,995315,845
Prepaid income taxes7,1635,425
Prepaid expenses and other current assets21,99120,665
Total current assets843,231802,424
Property and equipment, net336,808303,664
Intangible assets, net187,280242,675
Goodwill625,141633,467
Operating lease right-of-use assets96,352102,987
Deferred tax assets60,50348,003
Restricted cash and investments1,4941,494
Other assets24,13619,361
Total assets2,174,9452,154,075
Current liabilities:  
Accounts payable and accrued liabilities119,297115,614
Contingent consideration liabilities59,4777,986
Accrued payroll and related expenses60,88966,596
Operating lease liabilities10,0259,867
Income tax liabilities819828
Senior convertible notes446,8980
Total current liabilities697,405200,891
Long-term senior convertible notes443,533884,984
Deferred tax liabilities11,6973,049
Operating lease liabilities104,729111,592
Contingent consideration liabilities71,740139,824
Other long-term liabilities13,69518,528
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000 shares authorized, none outstanding00
Common stock, $0.001 par value; 150,000 shares authorized at September 30, 2022 and December 31, 2021; 58,880 shares issued and 52,076 outstanding at September 30, 2022; 58,469 shares issued and 51,769 outstanding at December 31, 20216363
Additional paid-in capital1,457,8281,434,976
Accumulated other comprehensive loss(4,355)(7,792)
Retained earnings62,03945,708
Treasury stock at cost; 6,804 shares and 6,700 shares at September 30, 2022 and December 31, 2021, respectively(683,429)(677,748)
Total equity832,146795,207
Total liabilities and equity$ 2,174,945$ 2,154,075